Publication | Closed Access
Femorodistal bypass using the chemically processed human umbilical vein graft: 9-year experience.
12
Citations
0
References
1990
Year
9-Year ExperienceSecondary Patency RateVenous DiseaseEndovascular TechniqueAcute IschemiaMedicineArterial ReconstructionsVascular SurgeryCord BloodSurgeryVascular AccessBiomedical EngineeringEndovascular ManagementArterial SubstituteFemorodistal BypassAnesthesiology
To evaluate patency, limb salvage rates and complications associated with the use of human umbilical vein as an arterial substitute, the authors carried out a retrospective review of 52 femorodistal bypasses performed over 9 years using human umbilical vein. Indications for operation included acute ischemia, rest pain and nonhealing ulceration or gangrene. There were 28 early occlusions, which resulted in a 1-month primary patency rate of 46% and a secondary patency rate of 52%. The primary and secondary patency rates at 1 year were 18% and 19% respectively. The mean limb salvage rate at 1 month was 57% and at 1 year 34%. Three aneurysms occurred (two anastomotic, one graft). Factors found to have a significant effect on patency rates were indication for operation and state of distal runoff. Infection occurred in 6% of grafts and led to amputation in every case. These disappointing results have caused the authors to discontinue use of human umbilical vein as an arterial substitute.